UnitedHealth Group Inc (UNH) Sustaining Returns

UnitedHealth reported USD figures for 2025 with revenue of about 91.4 billion, reflecting a modest year-over-year increase of 0.0597. EBIT and net income were not provided, limiting insight into operating efficiency. Depreciation and amortization totaled 4.36 billion, while CapEx data were not provided.

On a trailing basis, the company’s operating margin was 4.18% and net profit margin 2.69%. Return on equity stood at 12.5%, indicating solid capital productivity. The EV/EBITDA multiple of 13.469 and PE of 21.59 suggest the market values the business as a stable, mature operator.

Cash holdings were 24.37 billion against total debt of 12.14 billion, providing a comfortable liquidity position. However, missing EBIT and CapEx figures reduce visibility into reinvestment and free cash flow generation.

At a market price of USD 285.17, the shares trade below the value implied by the discounted cash flow model. The DCF analysis indicates meaningfully higher intrinsic value across all scenarios, suggesting the market discounts the company’s ability to sustain its returns.

With a trailing ROE of 12.5% and operating margin of 4.18%, the valuation gap implies investors expect limited improvement in profitability. The model’s higher fair value range points to potential upside if the company maintains its capital efficiency and steady revenue growth.